NF1 and neoplasm: These mutations lead to MAPK pathway hyperactivation and are strongly correlated with a high tumor mutational burden (TMB), which may enhance responsiveness to immune checkpoint inhibitors, though targeted therapies remain limited for NF1-mutant disease [79].